Ocular Therapeutix, Inc. (OCUL)
Largest Insider Buys in Sector
OCUL Insider Trading Activity
OCUL Median Price and Trade Amounts History Chart
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Insider Activity of Ocular Therapeutix, Inc.
Over the last 12 months, insiders at Ocular Therapeutix, Inc. have bought $7M and sold $734,912 worth of Ocular Therapeutix, Inc. stock.
On average, over the past 5 years, insiders at Ocular Therapeutix, Inc. have bought $6.18M and sold $392,970 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SUMMER ROAD LLC (10 percent owner) — $7M.
The last purchase of 930,851 shares for transaction amount of $7M was made by SUMMER ROAD LLC (10 percent owner) on 2024‑02‑26.
List of Insider Buy and Sell Transactions, Ocular Therapeutix, Inc.
| 2025-02-04 | Sale | See Remarks | 11,119 0.0073% | $7.81 | $86,839 | +1.79% | ||
| 2025-01-31 | Sale | See Remarks | 6,301 0.004% | $7.84 | $49,400 | +0.13% | ||
| 2024-11-25 | Sale | See Remarks | 20,680 0.013% | $9.01 | $186,327 | -6.05% | ||
| 2024-11-25 | Sale | Chief Scientific Officer | 2,948 0.0019% | $9.01 | $26,561 | -6.05% | ||
| 2024-11-25 | Sale | Chief Development Officer | 2,897 0.0018% | $9.01 | $26,102 | -6.05% | ||
| 2024-11-25 | Sale | Chief Strategy Officer | 1,814 0.0011% | $9.00 | $16,326 | -6.05% | ||
| 2024-08-23 | Sale | See Remarks | 20,880 0.0133% | $9.02 | $188,338 | -1.43% | ||
| 2024-08-23 | Sale | Chief Strategy Officer | 1,832 0.0012% | $9.02 | $16,525 | -1.43% | ||
| 2024-05-23 | Sale | See Remarks | 21,626 0.0139% | $5.79 | $125,215 | +47.41% | ||
| 2024-05-23 | Sale | Chief Strategy Officer | 2,274 0.0015% | $5.84 | $13,280 | +47.41% | ||
| 2024-02-26 | 10 percent owner | 930,851 0.6157% | $7.52 | $7M | -14.55% | |||
| 2024-02-05 | Sale | President and CEO | 19,642 0.0177% | $4.86 | $95,460 | +70.51% | ||
| 2024-02-05 | Sale | Chief Financial Officer | 6,212 0.0056% | $4.86 | $30,190 | +70.51% | ||
| 2024-02-05 | Sale | General Counsel | 6,029 0.0054% | $4.86 | $29,301 | +70.51% | ||
| 2024-02-05 | Sale | Chief Medical Officer | 6,346 0.0057% | $4.86 | $30,842 | +70.51% | ||
| 2024-02-05 | Sale | Chief Business Officer | 5,910 0.0053% | $4.86 | $28,723 | +70.51% | ||
| 2024-01-31 | Sale | President and CEO | 18,338 0.0168% | $4.95 | $90,773 | +73.66% | ||
| 2024-01-31 | Sale | Chief Financial Officer | 6,433 0.0059% | $4.95 | $31,843 | +73.66% | ||
| 2024-01-31 | Sale | General Counsel | 6,831 0.0063% | $4.95 | $33,813 | +73.66% | ||
| 2024-01-31 | Sale | Chief Medical Officer | 7,764 0.0071% | $4.95 | $38,432 | +73.66% |
Insider Historical Profitability
| SUMMER ROAD LLC | 10 percent owner | 8591401 5.4647% | $7.57 | 31 | 0 | +16.78% |
| Dugel Pravin | See Remarks | 791793 0.5036% | $7.57 | 0 | 3 | |
| Heier Jeffrey S. | Chief Scientific Officer | 269059 0.1711% | $7.57 | 2 | 1 | +22.62% |
| Kaiser Peter | Chief Development Officer | 213087 0.1355% | $7.57 | 0 | 1 | |
| Notman Donald | See Remarks | 193444 0.123% | $7.57 | 3 | 5 | +9.75% |
| Nayak Sanjay | Chief Strategy Officer | 174380 0.1109% | $7.57 | 0 | 3 | |
| Opaleye Management Inc. | 10 percent owner | 4918500 3.1285% | $7.57 | 2 | 0 | +99.18% |
| CHV II, L.P. | 10 percent owner | 2100138 1.3358% | $7.57 | 1 | 0 | +69.82% |
| Sawhney Amarpreet | Chairman of the Board | 1056031 0.6717% | $7.57 | 10 | 0 | +25.15% |
| Mattessich Antony C. | President and CEO | 588701 0.3745% | $7.57 | 6 | 3 | +1.23% |
| Strassburger Philip C. | General Counsel | 161493 0.1027% | $7.57 | 0 | 3 | |
| Ozden Rabia Gurses | Chief Medical Officer | 153054 0.0974% | $7.57 | 0 | 4 | |
| White Christopher G | Chief Business Officer | 123689 0.0787% | $7.57 | 0 | 3 | |
| Fortune James | Chief Operating Officer | 112060 0.0713% | $7.57 | 0 | 1 | |
| LINDSTROM RICHARD L MD | director | 90000 0.0572% | $7.57 | 1 | 1 | <0.0001% |
| Ankerud Eric | See Remarks | 78651 0.05% | $7.57 | 1 | 0 | +69.82% |
| SVLSF IV, LLC | 10 percent owner | 61084 0.0389% | $7.57 | 1 | 1 | +69.82% |
| Bollag Daniel M | See Remarks | 42100 0.0268% | $7.57 | 2 | 0 | +12.45% |
| Goldstein Michael H. | Chief Medical Officer | 25686 0.0163% | $7.57 | 2 | 0 | +41.08% |
| Hanley Kevin F. | See Remarks | 20000 0.0127% | $7.57 | 2 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 13419 0.0085% | $7.57 | 0 | 1 | |
| Warden Charles M | 13007 0.0083% | $7.57 | 0 | 2 | ||
| Versant Venture Capital III, L.P. | 10 percent owner | 13007 0.0083% | $7.57 | 0 | 2 | |
| Williams Leslie J. | director | 4500 0.0029% | $7.57 | 1 | 0 | +3.43% |
| PEACOCK BRUCE | director | 0 0% | $7.57 | 0 | 1 |
OCUL Institutional Investors: Active Positions
| Increased Positions | 76 | +43.43% | 10M | +6.99% |
| Decreased Positions | 65 | -37.14% | 13M | -9.59% |
| New Positions | 32 | New | 5M | New |
| Sold Out Positions | 19 | Sold Out | 4M | Sold Out |
| Total Postitions | 186 | +6.29% | 137M | -2.59% |
OCUL Ownership Change vs Market
Institutional Investor Ownership
| Summer Road Llc | $110,866.00 | 9.17% | 14.4M | -487,440 | -3.27% | 2024-09-30 |
| Vr Adviser, Llc | $98,271.00 | 8.13% | 12.76M | 0 | 0% | 2024-09-30 |
| Deep Track Capital, Lp | $97,955.00 | 8.1% | 12.72M | 0 | 0% | 2024-09-30 |
| Blackrock, Inc. | $87,427.00 | 7.23% | 11.35M | -166,162 | -1.44% | 2024-09-30 |
| Vanguard Group Inc | $64,558.00 | 5.34% | 8.38M | -227,918 | -2.65% | 2024-09-30 |
| Avoro Capital Advisors Llc | $62,062.00 | 5.13% | 8.06M | 0 | 0% | 2024-09-30 |
| Tcg Crossover Management, Llc | $40,957.00 | 3.39% | 5.32M | 0 | 0% | 2024-09-30 |
| Opaleye Management Inc. | $38,693.00 | 3.2% | 5.03M | -282,500 | -5.32% | 2024-09-30 |
| Citadel Advisors Llc | $32,801.00 | 2.71% | 4.26M | +205,976 | +5.08% | 2024-09-30 |
| Adage Capital Partners Gp, L.L.C. | $28,875.00 | 2.39% | 3.75M | +54,953 | +1.49% | 2024-09-30 |